CUGBP Elav-like family member 5Genealiases: BRUNOL-5 · BRUNOL5 · CELF-5
Q-omics provides the consensus-scored CELF5 profile across patient tissues and cancer cell-line models. CELF5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CELF5 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, CELF5 RNA expression shows 15,689 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, LUAD, and ACC as cancer lineages where CELF5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CELF5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CELF5 survival associations across molecular data types. CELF5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CELF5 RNA expression–survival associations across cancer types. High CELF5 expression shows unfavorable associations in UCS and ACC, but favorable associations in UVM, LGG, OV and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CELF5 RNA expression.
This table summarizes CELF5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CELF5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CELF5 shows lower tumor expression in BRCA and higher tumor expression in LUAD, KICH, LUSC, COAD and KIRP. The LUAD box plot shows higher CELF5 RNA expression in tumor versus normal tissue (log2 FC = +0.604, t-test p < 0.001).
This table shows molecular features associated with CELF5 in patient tissues and cancer cell lines. In patient samples, CELF5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CELF5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and OVARY.
